Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCRIT Dosing Regimens in Anemia of CKD
NCT00212875Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Sep 2005
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 2, randomised, open-label trial of epoetin alfa in anemia of chronic kidney disease (CKD-A) (5 arms), sponsored by Johnson & Johnson. Primary endpoints: Change in hemoglobin from baseline to end of study at 16 weeks and Maintenance of hemoglobin within 11-12 g/dL. Started Sep 2005; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT00212875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00212875.